All In Biotech

Drug Trial Radar · NCT03486990

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Last checked: Nov 19, 2026Latest source record: Jun 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Jan 23, 2018

Primary completion

May 24, 2019

Study completion Jul 22, 2019

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
COUR Pharmaceutical Development Company, Inc.
First posted
Apr 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease. The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and urine, and study subject health will also be monitored by vital signs such as blood pressure, electrocardiogram (ECG), and physical examination.

Conditions

  • Celiac Disease

Interventions

  • TIMP-GLIADrug

    intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Day 180
  2. Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse EventsTime frame: From Day 1 up to Day 180
  3. Number of Participants With Clinically Significant Physical Examination FindingsTime frame: From Day 1 up to Day 60
  4. Number of Participants With Clinically Significant Electrocardiograms (ECG) FindingsTime frame: From Day 1 up to Day 60
  5. Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation LevelsTime frame: From Day 1 up to Day 60
  6. Number of Participants With Clinically Significant Change From Baseline in Vital Signs ValuesTime frame: From Day 1 up to Day 60
  7. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3Time frame: Baseline (Day 1 pre-dose) and Day 3
  8. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7Time frame: Baseline (Day 1 pre-dose) and Day 7
  9. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8Time frame: Baseline (Day 1 pre-dose) and Day 8
  10. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10Time frame: Baseline (Day 1 pre-dose) and Day 10
  11. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14Time frame: Baseline (Day 1 pre-dose) and Day 14
  12. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38Time frame: Baseline (Day 1 pre-dose) and Day 38
  13. Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60Time frame: Baseline (Day 1 pre-dose) and Day 60
  14. Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1Time frame: Baseline (Day 1 pre-dose) and 15 minutes (min) post-dose on Day 1
  15. Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1Time frame: Baseline (Day 1 pre-dose) and 30 min post-dose on Day 1
  16. Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2Time frame: Baseline (Day 1 pre-dose) and Day 2
  17. Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and UrinalysisTime frame: From Day 1 up to Day 60
  18. Part A (Greater Than or Equal to [>=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release MarkersTime frame: Part A (>=4.0 mg/kg): Day 1 pre-dose up to 144 hours post-dose on Day 7; Part B: Day 8 pre-dose up to 144 hours post-dose on Day 14
  19. Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: From Day 1 up to Day 60

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Jacksonville Center For Clinical Research

    Jacksonville, Florida

  • Mass General Hospital Translational and Clinical Research Centers

    Boston, Massachusetts

  • Mayo Gastroenterology Research Unit

    Rochester, Minnesota

  • Prism Clinical Research

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.